BR112012010766A2 - composições e métodos de tratamento da colite e de outras doenças instestinais - Google Patents

composições e métodos de tratamento da colite e de outras doenças instestinais

Info

Publication number
BR112012010766A2
BR112012010766A2 BR112012010766A BR112012010766A BR112012010766A2 BR 112012010766 A2 BR112012010766 A2 BR 112012010766A2 BR 112012010766 A BR112012010766 A BR 112012010766A BR 112012010766 A BR112012010766 A BR 112012010766A BR 112012010766 A2 BR112012010766 A2 BR 112012010766A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
hif
diseases
treating colitis
Prior art date
Application number
BR112012010766A
Other languages
English (en)
Inventor
Joseph H Gardner
Robert Shalwitz
Original Assignee
Aerpio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerpio Therapeutics Inc filed Critical Aerpio Therapeutics Inc
Publication of BR112012010766A2 publication Critical patent/BR112012010766A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

composições e métodos de tratamento da colite e de outras doenças instestinais. são aqui revelados métodos de controle de atividade do fator-1 alfa de transcrição induzido por hipóxia (hif-1<244>) e de doenças, condições ou síndromes relacionadas a este como, dentre outras, e doença vascular periférica, a doença arterial coronariana, a insuficiência cardíaca, a isquemia e a anemia. são ainda reveladas composições farmacêuticas que compreendem inibidores de hif-1<244> prolil hidroxilase úteis para o tratamento de doenças, condições e/ou síndromes relacionadas á atividade do hif-1<244>
BR112012010766A 2009-11-06 2010-11-05 composições e métodos de tratamento da colite e de outras doenças instestinais BR112012010766A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25891409P 2009-11-06 2009-11-06
US25891809P 2009-11-06 2009-11-06
PCT/US2010/055691 WO2011057112A1 (en) 2009-11-06 2010-11-05 Methods for increasing the stabilization of hypoxia inducible factor-1 alpha

Publications (1)

Publication Number Publication Date
BR112012010766A2 true BR112012010766A2 (pt) 2015-10-06

Family

ID=43970365

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012010762-3A BR112012010762B1 (pt) 2009-11-06 2010-11-05 Compostos alquil piperazina-1-carboxilato inibidores de prolil hidroxilase e composição farmacêutica compreendendo os referidos compostos
BR112012010766A BR112012010766A2 (pt) 2009-11-06 2010-11-05 composições e métodos de tratamento da colite e de outras doenças instestinais

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112012010762-3A BR112012010762B1 (pt) 2009-11-06 2010-11-05 Compostos alquil piperazina-1-carboxilato inibidores de prolil hidroxilase e composição farmacêutica compreendendo os referidos compostos

Country Status (27)

Country Link
US (11) US8778412B2 (pt)
EP (9) EP2496236B1 (pt)
JP (6) JP5591939B2 (pt)
KR (8) KR101445946B1 (pt)
CN (3) CN102638983B (pt)
AU (3) AU2010314973B9 (pt)
BR (2) BR112012010762B1 (pt)
CA (3) CA2774043C (pt)
DK (4) DK2853265T3 (pt)
ES (5) ES2541613T3 (pt)
HK (4) HK1169275A1 (pt)
HR (3) HRP20130691T1 (pt)
HU (1) HUE026109T2 (pt)
IL (4) IL219610A (pt)
IN (3) IN2012DN04950A (pt)
MX (4) MX2012005275A (pt)
MY (3) MY163511A (pt)
NO (1) NO2853265T3 (pt)
NZ (4) NZ600405A (pt)
PL (4) PL2496084T3 (pt)
PT (4) PT2496236E (pt)
RS (3) RS54010B1 (pt)
RU (3) RU2521251C2 (pt)
SI (2) SI2496084T1 (pt)
SM (1) SMT201300096B (pt)
WO (3) WO2011057121A1 (pt)
ZA (1) ZA201204104B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMP200800060B (it) 2006-04-07 2009-07-14 Procter & Gamble Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptbeta) e loro usi
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
US9205129B2 (en) * 2009-10-09 2015-12-08 University Of Rochester Methods of treatment and screening assays for HIF-1α regulation
RU2521251C2 (ru) * 2009-11-06 2014-06-27 Аэрпио Терапьютикс Инк. Способы усиления стабилизации индуцируемого гипоксией фактора-1 альфа
NO2686520T3 (pt) 2011-06-06 2018-03-17
EP3251671A1 (en) * 2011-06-06 2017-12-06 Akebia Therapeutics Inc. Compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
NZ712479A (en) * 2013-03-15 2019-01-25 Univ Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3607821B1 (en) 2013-03-15 2022-08-03 EyePoint Pharmaceuticals, Inc. Compositions, formulations and methods for treating ocular diseases
PT3007695T (pt) 2013-06-13 2024-03-07 Akebia Therapeutics Inc Composições e métodos para tratamento de anemia
JP6549140B2 (ja) * 2014-02-19 2019-07-24 エアーピオ セラピューティクス インコーポレイテッド Ｎ−ベンジル−３−ヒドロキシ−４−置換ピリジン−２−（１ｈ）−オン
WO2015138882A1 (en) 2014-03-14 2015-09-17 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9539245B2 (en) 2014-08-07 2017-01-10 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of Tie-2
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
IL292262B2 (en) 2015-04-01 2024-02-01 Akebia Therapeutics Inc Formulation of an oral administration form of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid
US10953036B2 (en) 2017-11-20 2021-03-23 University Of Georgia Research Foundation, Inc. Compositions and methods of modulating HIF-2A to improve muscle generation and repair
AU2019265629A1 (en) 2018-05-09 2021-01-07 Akebia Therapeutics, Inc. Process for preparing 2-((5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino)acetic acid
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
WO2021119033A1 (en) * 2019-12-09 2021-06-17 Gb004, Inc. Compositions and methods of treatment
US20230167108A1 (en) * 2020-03-11 2023-06-01 Kissei Pharmaceutical Co., Ltd. Crystal of imidazopyridinone compound or salt thereof
WO2022036269A1 (en) * 2020-08-13 2022-02-17 Gb004, Inc. CRYSTALLINE FORMS OF AN HIF-1α PROLYL HYDROXYLASE INHIBITOR
WO2022036267A1 (en) * 2020-08-13 2022-02-17 Gb004, Inc. Compositions and methods of treatment
US20230113202A1 (en) * 2021-02-02 2023-04-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
KR102507532B1 (ko) * 2022-09-14 2023-03-10 주식회사 에이치디에스바이오 락토바실러스 플란타룸 hac03 균주 및 플라보노이드를 포함하는 염증성 장질환 예방 또는 치료용 조성물
CN116196314B (zh) * 2023-05-04 2023-08-15 广州市妇女儿童医疗中心 Ri-1或其盐在制备防治胃肠道疾病的药物中的应用

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US3853900A (en) * 1973-09-14 1974-12-10 Searle & Co 4-benzyloxy-2 (1h)-pyridones
US5358949A (en) * 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
TW219933B (pt) * 1990-02-26 1994-02-01 Lilly Co Eli
DE4221583A1 (de) * 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
DE4316077A1 (de) * 1993-05-13 1994-11-17 Bayer Ag Substituierte Mono- und Bihydridylmethylpyridone
DK0650960T3 (da) * 1993-11-02 1997-09-01 Hoechst Ag Substituerede heterocykliske carboxylsyreamid-estere, deres fremstilling og deres anvendelse som lægemidler.
CA2138929A1 (en) 1993-12-30 1995-07-01 Klaus Weidmann Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
US5789426A (en) * 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5849587A (en) * 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
CA2253282A1 (en) 1996-04-30 1997-11-06 Hoechst Aktiengesellschaft 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use as drugs
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
UA66370C2 (en) * 1997-12-16 2004-05-17 Lilly Co Eli Arylpiperazines having activity to setotonin 1 receptors
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
ATE438624T1 (de) 2000-12-28 2009-08-15 Shionogi & Co 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
WO2002074981A2 (en) * 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
EP2324834B1 (en) * 2001-12-06 2019-05-08 Fibrogen, Inc. Methods of Increasing Endogenous Erythropoietin (EPO)
JP4303121B2 (ja) 2002-01-11 2009-07-29 ロディアニル 硫化亜鉛のダニ駆除剤としての用途
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
JP4465276B2 (ja) 2002-10-16 2010-05-19 イシス イノベイション リミテッド アスパラギニルヒドロキシラーゼ及びその修飾物質
US6930117B2 (en) * 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
TWI344955B (en) * 2003-03-14 2011-07-11 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
SI1644336T1 (sl) 2003-06-06 2011-06-30 Fibrogen Inc Heteroarilne spojine, ki vsebujejo duĺ ik in njihova uporaba pri zviĺ anju endogenega eritropoetina
US20060251638A1 (en) 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
WO2005023328A2 (en) 2003-08-26 2005-03-17 Becton Dickinson And Company Methods for intradermal delivery of therapeutics agents
AU2004285351A1 (en) * 2003-10-31 2005-05-12 Earth Chemical Co., Ltd. Material in gel state
WO2005051933A1 (en) * 2003-11-28 2005-06-09 Ranbaxy Laboratories Limited An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby
CN101014571A (zh) 2004-01-30 2007-08-08 默克公司 用作hiv整合酶抑制剂的n－苄基－3,4－二羟基吡啶－2－羧酰胺类和n－苄基－2,3－二羟基吡啶－4－羧酰胺类化合物
US20050258126A1 (en) 2004-05-21 2005-11-24 Aniceto Canamasas Puigbo Double bottomed jar
US20080113383A1 (en) 2004-05-28 2008-05-15 Fibro Gen, Inc. Hif Prolyl Hydroxylase Activity Assay
US7718624B2 (en) * 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
US7588824B2 (en) * 2005-02-25 2009-09-15 The Regents Of The University Of California Hydrogen cyano fullerene containing proton conducting membranes
JP2008534630A (ja) * 2005-04-08 2008-08-28 ニューロメッド ファーマシューティカルズ リミテッド 疼痛の軽減のためのｎ型カルシウムチャネルブロッカーを含む組み合わせ治療の方法
US8177417B2 (en) * 2005-04-25 2012-05-15 Harsco Technologies Corporation Apparatus for continuous blending
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
EP1893186A2 (en) 2005-06-06 2008-03-05 Fibrogen, Inc. Improved treatment for anemia using a hif-alpha stabilising agent
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
PE20071020A1 (es) 2006-03-07 2007-12-11 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
US8968702B2 (en) 2006-03-30 2015-03-03 Duke University Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
SMP200800060B (it) 2006-04-07 2009-07-14 Procter & Gamble Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptbeta) e loro usi
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
TWI394747B (zh) 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
CA2659682C (en) 2006-06-26 2010-12-21 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
JP5265381B2 (ja) 2006-12-07 2013-08-14 テルモ株式会社 輸液チューブセット
US7635715B2 (en) * 2006-12-18 2009-12-22 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
US20100056563A1 (en) 2007-04-18 2010-03-04 Deodialsingh Guiadeen Novel 1.8-naphthyridine compounds
WO2008130508A1 (en) 2007-04-18 2008-10-30 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
WO2008137060A1 (en) 2007-05-04 2008-11-13 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
CA2685942A1 (en) 2007-05-16 2008-11-27 Merck & Co., Inc. Spiroindalones
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
EP2188295A4 (en) 2007-08-10 2011-11-16 Crystalgenomics Inc PYRIDINE DERIVATIVES AND METHODS OF USE
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
FR2924205B1 (fr) 2007-11-23 2013-08-16 Air Liquide Dispositif et procede de refrigeration cryogenique
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
WO2009070644A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009073497A2 (en) 2007-11-30 2009-06-11 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
BRPI0819418B1 (pt) 2007-12-13 2022-05-10 Archer-Daniels-Midland Company Método para a produção de etanol
JP2011507894A (ja) 2007-12-19 2011-03-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
WO2009089547A1 (en) 2008-01-11 2009-07-16 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
RU2014146121A (ru) 2009-01-12 2015-06-10 Аэрпио Терапьютикс Инк. Способы лечения синдрома сосудистой утечки
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
PL2451279T3 (pl) 2009-07-06 2019-09-30 Aerpio Therapeutics, Inc. Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych
RU2521251C2 (ru) 2009-11-06 2014-06-27 Аэрпио Терапьютикс Инк. Способы усиления стабилизации индуцируемого гипоксией фактора-1 альфа
KR101823924B1 (ko) 2010-10-07 2018-01-31 에르피오 세러퓨틱스 인코포레이티드 안구 부종, 신생혈관화 및 관련 질환의 치료를 위한 조성물 및 방법
EP3251671A1 (en) 2011-06-06 2017-12-06 Akebia Therapeutics Inc. Compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
US8999325B2 (en) 2011-10-13 2015-04-07 Aerpio Therapeutics, Inc Treatment of ocular disease
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
EP3607821B1 (en) 2013-03-15 2022-08-03 EyePoint Pharmaceuticals, Inc. Compositions, formulations and methods for treating ocular diseases
JP6549140B2 (ja) 2014-02-19 2019-07-24 エアーピオ セラピューティクス インコーポレイテッド Ｎ−ベンジル−３−ヒドロキシ−４−置換ピリジン−２−（１ｈ）−オン
US9839422B2 (en) 2014-02-24 2017-12-12 Ethicon Llc Implantable layers and methods for altering implantable layers for use with surgical fastening instruments

Also Published As

Publication number Publication date
ES2644998T3 (es) 2017-12-01
CA2774046A1 (en) 2011-05-12
AU2010314976A1 (en) 2012-06-21
KR20140095105A (ko) 2014-07-31
EP2952192A1 (en) 2015-12-09
EP2496084A4 (en) 2012-11-21
AU2010314973B2 (en) 2014-08-28
MY163511A (en) 2017-09-15
PL2853265T3 (pl) 2018-01-31
US8999971B2 (en) 2015-04-07
DK2496236T3 (da) 2013-07-08
EP2496084A1 (en) 2012-09-12
US9278930B2 (en) 2016-03-08
HK1208806A1 (en) 2016-03-18
IN2012DN04940A (pt) 2015-09-25
US9540326B2 (en) 2017-01-10
CN102638983B (zh) 2014-11-26
EP3698794A1 (en) 2020-08-26
JP5591939B2 (ja) 2014-09-17
EP2952192B1 (en) 2019-05-15
JP2014159427A (ja) 2014-09-04
IN2012DN04950A (pt) 2015-09-25
NZ629733A (en) 2016-02-26
EP2496236A1 (en) 2012-09-12
US8536181B2 (en) 2013-09-17
IL219610A (en) 2015-07-30
NZ600405A (en) 2014-08-29
MX365138B (es) 2019-05-24
ZA201204104B (en) 2013-02-27
AU2010314982A1 (en) 2012-06-21
JP2013508463A (ja) 2013-03-07
KR20150116464A (ko) 2015-10-15
AU2010314973A1 (en) 2012-06-21
RS52870B (en) 2013-12-31
JP5865411B2 (ja) 2016-02-17
RU2518071C2 (ru) 2014-06-10
JP2014139206A (ja) 2014-07-31
US20110111058A1 (en) 2011-05-12
CN102595896B (zh) 2016-02-17
EP2496084B1 (en) 2015-06-10
EP2496082B1 (en) 2016-10-12
EP2853265B1 (en) 2017-07-26
CA2774046E (en) 2011-05-12
IL219612A (en) 2016-11-30
JP5627040B2 (ja) 2014-11-19
CN102638983A (zh) 2012-08-15
US8883774B2 (en) 2014-11-11
HRP20150473T1 (hr) 2015-06-05
KR20120088833A (ko) 2012-08-08
MX2012005275A (es) 2012-06-19
NZ600400A (en) 2014-09-26
SI2649998T1 (sl) 2015-06-30
HK1169313A1 (en) 2013-01-25
SI2496084T1 (sl) 2015-08-31
RU2521251C2 (ru) 2014-06-27
IL219610A0 (en) 2012-07-31
KR101483831B1 (ko) 2015-01-21
JP2013508462A (ja) 2013-03-07
PT2649998E (pt) 2015-04-21
EP2649998A1 (en) 2013-10-16
BR112012010762B1 (pt) 2021-08-03
MX2012005274A (es) 2012-06-19
KR20140048341A (ko) 2014-04-23
US20170298019A1 (en) 2017-10-19
JP5599467B2 (ja) 2014-10-01
US20190055198A1 (en) 2019-02-21
US9045495B2 (en) 2015-06-02
KR20120079846A (ko) 2012-07-13
US20110110961A1 (en) 2011-05-12
PL2496236T3 (pl) 2013-10-31
RS54124B1 (en) 2015-12-31
US20130158045A1 (en) 2013-06-20
US10562854B2 (en) 2020-02-18
KR20140122283A (ko) 2014-10-17
WO2011057112A1 (en) 2011-05-12
CN102612367B (zh) 2014-02-19
EP2649998B1 (en) 2015-03-04
ES2424122T3 (es) 2013-09-27
EP2496082A4 (en) 2012-11-21
US8778412B2 (en) 2014-07-15
US20150218098A1 (en) 2015-08-06
PT2496236E (pt) 2013-07-08
RU2012123387A (ru) 2013-12-20
ES2782999T3 (es) 2020-09-16
EP2954899B1 (en) 2020-01-08
JP5961665B2 (ja) 2016-08-02
AU2010314973B9 (en) 2015-03-19
EP3603644A1 (en) 2020-02-05
DK2649998T3 (en) 2015-05-04
US20140364419A1 (en) 2014-12-11
US20130158010A1 (en) 2013-06-20
KR20120079844A (ko) 2012-07-13
RU2012123388A (ru) 2013-12-20
US20220185778A1 (en) 2022-06-16
KR20150016414A (ko) 2015-02-11
PT2496084E (pt) 2015-08-21
RU2518416C2 (ru) 2014-06-10
HRP20150772T1 (hr) 2015-08-28
JP2013508464A (ja) 2013-03-07
US20150157617A1 (en) 2015-06-11
US20110112055A1 (en) 2011-05-12
KR101445946B1 (ko) 2014-09-29
MY161880A (en) 2017-05-15
RU2012123386A (ru) 2013-12-20
US8309537B2 (en) 2012-11-13
MX2012005273A (es) 2012-06-19
ES2533128T3 (es) 2015-04-07
EP2496236A4 (en) 2012-09-12
HK1190334A1 (en) 2014-07-04
AU2010314976B2 (en) 2014-03-06
CN102612367A (zh) 2012-07-25
HUE026109T2 (en) 2016-05-30
PL2496236T4 (pl) 2015-11-30
NO2853265T3 (pt) 2017-12-23
PT2853265T (pt) 2017-11-07
WO2011057115A1 (en) 2011-05-12
CA2774039A1 (en) 2011-05-12
SMT201300096B (it) 2013-11-08
HK1169275A1 (en) 2013-01-25
ES2541613T3 (es) 2015-07-22
IL219611A0 (en) 2012-07-31
EP2496236B1 (en) 2013-05-01
PL2496084T3 (pl) 2015-09-30
CA2774046C (en) 2014-01-21
RS54010B1 (en) 2015-10-30
BR112012010762A2 (pt) 2018-03-20
JP2014221826A (ja) 2014-11-27
IL239918A0 (en) 2015-08-31
IN2012DN04949A (pt) 2015-09-25
AU2010314982B2 (en) 2013-08-29
CA2774043A1 (en) 2011-05-12
NZ600396A (en) 2014-08-29
EP2496082A1 (en) 2012-09-12
IL219611A (en) 2017-03-30
WO2011057121A1 (en) 2011-05-12
DK2496084T3 (en) 2015-06-29
HRP20130691T1 (en) 2013-10-11
BR112012010759A2 (pt) 2015-10-06
CN102595896A (zh) 2012-07-18
DK2853265T3 (da) 2017-11-06
KR101591701B1 (ko) 2016-02-05
CA2774043C (en) 2015-04-14
PL2649998T3 (pl) 2015-08-31
EP2853265A1 (en) 2015-04-01
IL219612A0 (en) 2012-07-31
KR101613103B1 (ko) 2016-04-18
MY160066A (en) 2017-02-15
EP2954899A1 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
BR112012010766A2 (pt) composições e métodos de tratamento da colite e de outras doenças instestinais
DK3357911T3 (da) Prolylhydroxylaseinhibitorer og fremgangsmåder til anvendelse
BRPI0508931A (pt) ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico
NI200700296A (es) Imidazoquinolinas como inhibidores de cinasa de lipido
BR112012029656A2 (pt) composições para uso no tratamento ou diagnóstico de disturbios ósseos e/ou distúrbios cardiovasculares
BR112013026494A2 (pt) composto, composição farmacêutica, método para tratar condição
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
NO20084919L (no) Oksadiazolidindionforbindelse
DOP2010000011A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CY1113556T1 (el) Παραγωγα πυραζολο πυριδινης ως αναστολεις της nadph οξειδασης
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
NO20071930L (no) t4Metoder og sammensetninger til behandling av hyperlipidemi.
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
BRPI0610108B8 (pt) compostos promotores de apoptose e composição que compreende os ditos compostos
NO20085218L (no) Nye pyridinanaloger
BR112012002134B8 (pt) compostos inibidores de apaf-1
BRPI0510697A (pt) gm3 sintase como um alvo terapêutico em complicações micro-vasculares da diabete
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
WO2009158031A3 (en) Methods and compositions for therapeutic treatment
EA200870433A1 (ru) Азагетероциклильные производные андростанов и андростенов в качестве лекарственных средств от сердечно-сосудистых расстройств
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
NO20076405L (no) Anvendelse av 24-nor-UDCA
BR112016028750A2 (pt) ?métodos para tratar, prevenir, ou melhorar pelo menos um sintoma associado e para diagnosticar e monitorar insuficiência cardíaca ou fibrilação atrial, inibidor da lisil oxidase ativa ou proteína lisil tipo oxidase, e, composição?
Lee et al. Structure–activity relationship of the 7-hydroxy benzimidazole analogs as glycogen synthase kinase 3β inhibitor
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL